Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Abstract Objectives Bispecific antibodies targeting CD47 and PD‐L1 (CD47 × PD‐L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti‐CD47‐mediated toxicity, the effect of combined innate and adaptive immune activation on protective tumor‐resident CD8+ T cel...

Full description

Saved in:

Bibliographic Details
Main Authors:	Susan N Christo, Keely M McDonald, Thomas N Burn, Nadia Kurd, Jessica Stanfield, Megan M Kaneda, Ruth Seelige, Christopher P Dillon, Timothy S Fisher, Bas Baaten, Laura K Mackay
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Clinical & Translational Immunology
Subjects:	adaptive immunity CD47 CD8+ T cells immune checkpoint blockade immunotherapy tumor‐resident CD8+ T cells
Online Access:	https://doi.org/10.1002/cti2.70014
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)

Two chemotherapeutic agents expand stem-like CD62L+CD8+ T cells in antitumor immune responses
by: Xiaokang Ruan, et al.
Published: (2025-04-01)

CYTOTOXIC ACTIVITY OF DENDRITIC CELLS AGAINST ACTIVATED CD4+ AND CD8+T-LYMPHOCYTES IN THE CULTURE IN VITRO
by: T. V. Tyrinova, et al.
Published: (2012-05-01)

Association of Absolute Lymphocyte Count and Circulating CD4+ and CD8+ T-Cells with Positive Clinical Outcome in Survivors of Cancer: An Observational Study
by: Suresh Rao, et al.
Published: (2019-07-01)

Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response
by: Qian Gou, et al.
Published: (2025-02-01)

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy
by: Coralie Schoumacher, et al.
Published: (2024-12-01)

Systematic exploration of the molecular characteristics of CD8+ T cells to predict the response to immunotherapy and the prognosis of patients with colon adenocarcinoma
by: Xin Shen, et al.
Published: (2024-12-01)

Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype
by: Jingjing Qu, et al.
Published: (2025-07-01)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
by: Jian‐Hua Wang, et al.
Published: (2019-03-01)

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma
by: Aiping Lin, et al.
Published: (2024-12-01)

Immunosenescence markers in T- and NK-cells according to the CD4/CD8 ratio in successfully treated people living with HIV
by: Matteo Vassallo, et al.
Published: (2025-04-01)

The role of CD47 in immune escape of colon cancer and its correlation with heterogeneity of tumor immune microenvironment
by: Qiu-Si Tian, et al.
Published: (2024-12-01)

Expansion of CD57+ CD8 T cells in common variable immunodeficiency with hepatopathy and CMV infection
by: Patrick Bez, et al.
Published: (2025-05-01)

Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study
by: Jiaye Liu, et al.
Published: (2020-01-01)

CD4+T and CD8+T cells profile in lung inflammation and fibrosis: targets and potential therapeutic drugs
by: Xiaobo Sun, et al.
Published: (2025-05-01)

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy
by: Mithunah Krishnamoorthy, et al.
Published: (2025-02-01)

Activin A promoted the anti‐tumor effect of ActRIIA high CD8+ T cells in mouse hepatoma
by: Liangchang Hu, et al.
Published: (2025-01-01)

COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China
by: Yanyan Li, et al.
Published: (2024-12-01)

CD4+/CD8+ lymphocyte ratio as a biomarker of morbidity and severity in patients with moderate and severe COVID-19
by: D. Torres-Gonzales, et al.
Published: (2025-07-01)

Characterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme
by: Hong-Liang Wang, et al.
Published: (2025-05-01)

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines
by: Cynthia González Muñoz, et al.
Published: (2025-05-01)

The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma
by: Asim Armagan Aydin, et al.
Published: (2024-11-01)

Knockdown of CSF1R molecules enhances the antitumor effects of CD8+ T lymphocytes in bladder cancer
by: Jingxuan Peng, et al.
Published: (2025-07-01)

Immunotherapeutic Blockade of CD47 Increases Virus Neutralization Antibodies
by: Lamin B. Cham, et al.
Published: (2025-05-01)

CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis
by: Yunmi Ko, et al.
Published: (2024-11-01)

The function of T cells in immune thrombocytopenia
by: Siyuan Bu, et al.
Published: (2025-02-01)

CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway
by: Rongpu Liang, et al.
Published: (2025-02-01)

The significance of CD4+ and CD8+ T lymphocyte infiltration in esophageal squamous cell carcinoma
by: Jiang Y. Zhao, et al.
Published: (2025-01-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

The unreversible reduced but persistent activated NK and CD8+ T cells in severe/critical COVID-19 during omicron pandemic in China
by: Ling Qin, et al.
Published: (2023-12-01)

CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients
by: Lingyu Zhang, et al.
Published: (2025-05-01)

A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
by: Liping Qin, et al.
Published: (2024-12-01)

Immunohistochemical analysis of PD-L1, CD4, CD8, CD20, and PU.1 expression in a dedifferentiated chondrosarcoma: the clinical and prognostic value
by: Olga V. Kovaleva, et al.
Published: (2025-07-01)

Intratumoral CD8+ tumor-infiltrating lymphocytes as prognostic predictors in radio-chemoradiotherapy-treated nasopharyngeal carcinoma
by: Xinjing Li, et al.
Published: (2025-05-01)

CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus
by: Jingjing Qu, et al.
Published: (2024-12-01)

Research of subpopulation CD3+ CD4- CD8- double-negative T lymphocytes in kidney transplant recipients
by: S. V. Zybleva, et al.
Published: (2020-03-01)

Identification of a risk model for prognostic and therapeutic prediction in bladder urothelial carcinoma based on infiltrating CD8+ T cells
by: Ligang Ma, et al.
Published: (2025-12-01)

Overexpression of ST8Sia1 inhibits tumor progression by TGF-β1 signaling in rectal adenocarcinoma and promotes the tumoricidal effects of CD8+ T cells by granzyme B and perforin
by: Chang Zhang, et al.
Published: (2025-12-01)

Identification of immune subtypes associated with CD8+ T cell-related genes providing new treatment strategies of esophageal carcinoma
by: Youyi Wu, et al.
Published: (2025-02-01)

Functional characterisation of CD8+ T cells mobilised with acute supramaximal high‐intensity interval exercise: implications for immune surveillance
by: Anna Strömberg, et al.
Published: (2025-01-01)